Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.

ABSTRACT:

Background

Biological therapies (BTs) including infliximab (IFX), adalimumab (ADL), secukinumab (SCK) and ustekinumab (UST) are approved in Japan for the treatment of psoriasis. Although the persistence rates and medical costs of BTs treatment have been investigated in multiple foreign studies in recent years, few such studies have been conducted in Japan and the differences between patients who adhered to treatment and those who did not have not been reported. This study is aimed at investigating the persistence rates and medical costs of BTs in the treatment of psoriasis in Japan, using the real-world data from a large-scale claims database.

Methods

Claims data from the JMDC database (August 2009 to December 2016) were used for this analysis. Patient data were extracted us

SUBMITTER: Sruamsiri R 

PROVIDER: S-EPMC6042444 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature